

**Copper-Catalyzed Direct Oxidative Annulation of *N*-Iminopyridinium Ylides  
with Terminal Alkynes Using O<sub>2</sub> as Oxidant**

(Supporting Information)

Shengtao Ding,<sup>†</sup> Yuepeng Yan,<sup>†</sup> and Ning Jiao<sup>\*†‡</sup>

<sup>†</sup> State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences,  
Peking University, Xue Yuan Rd. 38, Beijing 100191, China,

<sup>‡</sup> State Key Laboratory of Organometallic Chemistry, Chinese Academy of Sciences, Shanghai  
200032, China.

E-mail: [jiaoning@bjmu.edu.cn](mailto:jiaoning@bjmu.edu.cn)

Fax: (+86)10-82805297


**CONTENTS:**

General Information.....	2
Experimental procedures and characterization of products.....	4
Kinetic Isotopic Experiment Study.....	12
References.....	14

## General Information


All manipulations were conducted with a standard Schlenk technique under oxygen atmosphere (1 atm).  $^1\text{H}$ -NMR spectra were recorded with a Bruker AVIII-400 spectrometer. Chemical shifts (in ppm) were referenced to tetramethylsilane ( $\delta = 0$  ppm) in  $\text{CDCl}_3$  as an internal standard.  $^{13}\text{C}$ -NMR spectra were obtained by the same NMR spectrometer and were calibrated with  $\text{CDCl}_3$  ( $\delta = 77.00$  ppm). Mass spectra were recorded by PE SCLEX QSTAR spectrometer. Unless otherwise noted, materials obtained from commercial suppliers were used without further purification. Compounds **1a**,<sup>1</sup> **1b** – **1f**<sup>2</sup> were synthesized according to related literatures.

**Table S1.** Optimization of the reaction conditions.<sup>a</sup>



entry	[Cu]	[Ag]	base	solvent	yield(%) <sup>b</sup>
1	CuI			PhCl	trace
2	CuI	Ag <sub>2</sub> CO <sub>3</sub>		PhCl	27
3	CuI	Ag <sub>2</sub> CO <sub>3</sub>	Na <sub>2</sub> CO <sub>3</sub>	PhCl	55
4	CuI	Ag <sub>2</sub> CO <sub>3</sub>	K <sub>2</sub> CO <sub>3</sub>	PhCl	<5
5	CuI	Ag <sub>2</sub> CO <sub>3</sub>	Cs <sub>2</sub> CO <sub>3</sub>	PhCl	<5
6	CuI	Ag <sub>2</sub> CO <sub>3</sub>	DABCO	PhCl	74
7	CuI		DABCO	PhCl	20
8	Cu(OAc) <sub>2</sub>	Ag <sub>2</sub> CO <sub>3</sub>	DABCO	PhCl	23
9	CuCN	Ag <sub>2</sub> CO <sub>3</sub>	DABCO	PhCl	40
10	CuBr <sub>2</sub>	Ag <sub>2</sub> CO <sub>3</sub>	DABCO	PhCl	20
11	CuCl <sub>2</sub>	Ag <sub>2</sub> CO <sub>3</sub>	DABCO	PhCl	35
12	CuI	AgOAc	DABCO	PhCl	45
13	CuI	Ag <sub>2</sub> O	DABCO	PhCl	38
14	CuI	AgOBz	DABCO	PhCl	49
15	CuI	AgOTs	DABCO	PhCl	52
16	CuI	Ag <sub>2</sub> CO <sub>3</sub>	DABCO	DMF	<5
17	CuI	Ag <sub>2</sub> CO <sub>3</sub>	DABCO	DMSO	0
18	CuI	Ag <sub>2</sub> CO <sub>3</sub>	DABCO	NMP	0
19 <sup>c</sup>	CuI	Ag <sub>2</sub> CO <sub>3</sub>	DABCO	PhCl	36
20 <sup>d</sup>	CuI	Ag <sub>2</sub> CO <sub>3</sub>	DABCO	PhCl	20


<sup>a</sup> General condition: **1a** (0.2 mmol), **2a** (0.6 mmol), additives, solvent (2 mL) under O<sub>2</sub> (1 atm) for 48 h. <sup>b</sup> Isolated yields. <sup>c</sup> The reaction was carried out under 100 °C. <sup>d</sup> The reaction was carried out under air.



**Scheme S1.** Kinetic isotope effect experiment.


## Experimental procedures and characterization of products

### 1. 2-Phenylpyrazolo[1,5-*a*]pyridine (**3a**)<sup>3</sup>




**Typical procedure:** Substrate **1a** (39.6 mg, 0.20 mmol), CuI (3.8 mg, 10 mol %), Ag<sub>2</sub>CO<sub>3</sub> (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv) were added to a 20 mL Schlenk tube under O<sub>2</sub>, followed by addition of **2a** (66 μL, 0.60 mmol) and PhCl (2.0 mL). The formed mixture was stirred at 125 °C under O<sub>2</sub> (1 atm.) for 48 h as monitored by TLC. The solution was then cooled to rt., diluted with ethyl acetate (15 mL), and evaporated under vacuum. The crude product was purified by column chromatography on silica gel (hexane : ethyl acetate = 10:1) to afford 29.3 mg (74%) of product **3a**: light yellow solid; m.p. 95-97 °C (*n*-hexane/ethyl acetate); IR: (KBr) ν<sub>max</sub> 1944, 1889, 1632, 1512, 1470, 1332, 762 cm<sup>-1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>) δ 8.46 (d, *J* = 7.2 Hz, 1 H), 7.96 (d, *J* = 8.0 Hz, 2 H), 7.51-7.42 (m, 3 H), 7.36 (t, *J* = 7.2 Hz, 1 H), 7.06 (t, *J* = 8.0 Hz, 1 H), 6.78 (s, 1 H), 6.71 (dt, *J* = 1.2, 7.2 Hz, 1 H); <sup>13</sup>C NMR: (100 MHz, CDCl<sub>3</sub>) δ 153.5, 141.6, 133.2, 128.7, 128.5, 128.4, 126.4, 123.4, 117.9, 111.6, 93.7; MS (EI) *m/z* (relative intensity) 194.1 (100) [M]<sup>+</sup>.

### 2. 2-*o*-Tolylpyrazolo[1,5-*a*]pyridine (**3b**)<sup>3</sup>




The reaction of **1a** (39.6 mg, 0.20 mmol), 1-ethynyl-2-methylbenzene (78 μL, 0.60 mmol), CuI (3.8 mg, 10 mol %), Ag<sub>2</sub>CO<sub>3</sub> (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 34.2 mg (82%) of **3b**: light beige solid; m.p. 70-73 °C (*n*-hexane/ethyl acetate); IR: (KBr) ν<sub>max</sub> 1752, 1633, 1520, 1508, 1461, 1329, 1251, 762 cm<sup>-1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>) δ 8.47 (d, *J* = 7.2 Hz, 1 H), 7.67 (t, *J* = 3.6 Hz, 1 H), 7.50 (d, *J* = 9.2 Hz, 1 H), 7.30-7.23 (m, 3 H), 7.08 (t, *J* = 8.0 Hz, 1 H), 6.72 (t, *J* = 7.2 Hz, 1 H), 6.62 (s, 1 H), 2.53 (s, 3 H); <sup>13</sup>C NMR: (100 MHz, CDCl<sub>3</sub>) δ 154.0, 140.7, 136.4, 133.1, 130.8, 129.9, 128.4, 128.1, 125.8, 123.2, 117.8, 111.4, 96.9, 21.1; MS (EI) *m/z* (relative intensity) 208.2 (82), 207.2 (100) [M]<sup>+</sup>.

### 3. 2-*m*-Tolylpyrazolo[1,5-*a*]pyridine (**3c**)




The reaction of **1a** (39.6 mg, 0.20 mmol), 1-ethynyl-3-methylbenzene (81  $\mu$ l, 0.60 mmol), CuI (3.8 mg, 10 mol %), Ag<sub>2</sub>CO<sub>3</sub> (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 33.9 mg (81%) of **3c**: light yellow solid; m.p. 87-88 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\max}$  1755, 1634, 1520, 1467, 1419, 1331, 1256, 772, 733 cm<sup>-1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.46 (d, *J* = 6.8 Hz, 1 H), 7.81 (s, 1H), 7.74 (d, *J* = 8.0 Hz, 1 H), 7.48 (d, *J* = 9.2 Hz, 1 H), 7.34 (t, *J* = 7.6 Hz, 1 H), 7.18 (d, *J* = 7.2 Hz, 1 H), 7.06 (t, *J* = 7.6 Hz, 1 H), 6.77 (s, 1 H), 6.70 (t, *J* = 6.8 Hz, 1 H), 2.42 (s, 3 H); <sup>13</sup>C NMR: (100 MHz, CDCl<sub>3</sub>)  $\delta$  153.7, 141.6, 138.3, 133.1, 129.2, 128.6, 128.4, 127.0, 123.6, 123.3, 117.8, 111.6, 93.7, 21.4; MS (EI) *m/z* (relative intensity) 208.2 (100) [M]<sup>+</sup>; HRMS *m/z* (ESI) calcd. for C<sub>14</sub>H<sub>13</sub>N<sub>2</sub> (M + H)<sup>+</sup> 209.1073, found 209.1077.

### 4. 2-*p*-Tolylpyrazolo[1,5-*a*]pyridine (**3d**)<sup>3</sup>



The reaction of **1a** (39.6 mg, 0.20 mmol), 1-ethynyl-4-methylbenzene (78  $\mu$ l, 0.60 mmol), CuI (3.8 mg, 10 mol %), Ag<sub>2</sub>CO<sub>3</sub> (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 31.6 mg (76%) of **3d**: light yellow solid; m.p. 106-108 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\max}$  1909, 1633, 1514, 1474, 1331, 1255, 825, 778, 763 cm<sup>-1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.45 (d, *J* = 6.8 Hz, 1 H), 7.85 (d, *J* = 8.0 Hz, 2 H), 7.48 (d, *J* = 8.8 Hz, 1 H), 7.25 (d, *J* = 7.2 Hz, 2 H), 7.06 (t, *J* = 8.0 Hz, 1 H), 6.75 (s, 1 H), 6.70 (t, *J* = 6.4 Hz, 1 H), 2.39 (s, 3 H); <sup>13</sup>C NMR: (100 MHz, CDCl<sub>3</sub>)  $\delta$  153.6, 141.6, 138.2, 130.4, 129.4, 128.5, 126.3, 123.3, 117.8, 111.5, 93.4, 21.3; MS (EI) *m/z* (relative intensity) 208.2 (100) [M]<sup>+</sup>.


### 5. 2-(4-*tert*-Butylphenyl)pyrazolo[1,5-*a*]pyridine (**3e**)



The reaction of **1a** (39.6 mg, 0.20 mmol), 1-*tert*-butyl-4-ethynylbenzene (84  $\mu$ l, 0.60 mmol), CuI (3.8 mg, 10 mol %), Ag<sub>2</sub>CO<sub>3</sub> (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 36.5 mg (73%) of **3e**:


white solid; m.p. 108-110 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\max}$  1918, 1751, 1632, 1513, 1473, 1328, 841, 776  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR: (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.46 (d,  $J$  = 6.8 Hz, 1 H), 7.89 (d,  $J$  = 8.4 Hz, 2 H), 7.49-7.45 (m, 3 H), 7.08-7.02 (m, 1 H), 6.76 (s, 1 H), 6.69 (t,  $J$  = 6.8 Hz, 1 H), 1.36 (s, 9H);  $^{13}\text{C}$  NMR: (100 MHz,  $\text{CDCl}_3$ )  $\delta$  153.6, 151.4, 141.6, 130.4, 128.5, 126.2, 125.6, 123.3, 117.8, 111.4, 93.5, 34.6, 31.3; MS (EI)  $m/z$  (relative intensity) 250.2 (36), 235.2 (100)  $[\text{M}]^+$ ; HRMS  $m/z$  (ESI) calcd. for  $\text{C}_{17}\text{H}_{19}\text{N}_2$  ( $\text{M} + \text{H}$ ) $^+$  251.1543, found 251.1548.

## 6. 2-(4-Methoxyphenyl)pyrazolo[1,5-*a*]pyridine (**3f**)<sup>3,4</sup>



The reaction of **1a** (39.6 mg, 0.20 mmol), 1-ethynyl-4-methoxybenzene (82  $\mu\text{l}$ , 0.60 mmol), CuI (3.8 mg, 10 mol %),  $\text{Ag}_2\text{CO}_3$  (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 31.3 mg (70%) of **3f**: white solid; m.p. 111-114 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\max}$  2363, 1858, 1631, 1613, 1514, 1463, 1246, 1029, 772  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR: (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.44 (d,  $J$  = 6.4 Hz, 1 H), 7.89 (d,  $J$  = 8.8 Hz, 2 H), 7.46 (d,  $J$  = 9.2 Hz, 1 H), 7.05 (t,  $J$  = 7.6 Hz, 1 H), 6.98 (d,  $J$  = 9.2 Hz, 2 H), 6.80-6.66 (m, 2 H), 3.84 (s, 3 H);  $^{13}\text{C}$  NMR: (100 MHz,  $\text{CDCl}_3$ )  $\delta$  159.9, 153.4, 141.6, 128.4, 127.7, 125.9, 123.3, 117.7, 114.1, 111.3, 93.0, 55.3; MS (EI)  $m/z$  (relative intensity) 224.2 (100), 209.1 (56)  $[\text{M}]^+$ .


## 7. 2-(4-Bromophenyl)pyrazolo[1,5-*a*]pyridine (**3g**)



The reaction of **1a** (39.6 mg, 0.20 mmol), 1-bromo-4-ethynylbenzene (108.6 mg, 0.60 mmol), CuI (3.8 mg, 10 mol %),  $\text{Ag}_2\text{CO}_3$  (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 44.9 mg (82%) of **3g**: white solid; m.p. 174-177 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\max}$  2851, 1727, 1634, 1506, 1467, 1427, 1069, 1010, 775  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR: (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.44 (d,  $J$  = 6.4 Hz, 1 H), 7.82 (d,  $J$  = 8.4 Hz, 2 H), 7.56 (d,  $J$  = 8.0 Hz, 2 H), 7.49 (d,  $J$  = 8.8 Hz, 1 H), 7.11-7.05 (m, 1 H), 6.76-6.71 (m, 2 H);  $^{13}\text{C}$  NMR: (100 MHz,  $\text{CDCl}_3$ )  $\delta$  152.4, 141.7, 132.2, 131.8, 128.5, 128.0, 123.6, 122.4, 117.9, 111.9, 93.7; MS (EI)

$m/z$  (relative intensity) 272.1 (7), 192.0 (12), 117.0 (20), 62.6 (100)  $[M]^+$ ; HRMS  $m/z$  (ESI) calcd. for  $C_{13}H_{10}N_2Br$  ( $M + H$ ) $^+$  273.0022, found 273.0029.


### 8. 2-(4-Chlorophenyl)pyrazolo[1,5-*a*]pyridine (3h)



**3h**

The reaction of **1a** (39.6 mg, 0.20 mmol), **2b** (82.0 mg, 0.60 mmol), CuI (3.8 mg, 10 mol %),  $Ag_2CO_3$  (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 40.5 mg (89%) of **3h**: light yellow solid; m.p. 158-160 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{max}$  1899, 1634, 1508, 1469, 1090, 1012, 774  $cm^{-1}$ ;  $^1H$  NMR: (400 MHz,  $CDCl_3$ )  $\delta$  8.45 (d,  $J = 7.2$  Hz, 1 H), 7.89 (d,  $J = 8.4$  Hz, 2 H), 7.50 (d,  $J = 9.2$  Hz, 1 H), 7.41 (d,  $J = 8.0$  Hz, 2 H), 7.09 (t,  $J = 8.0$  Hz, 1 H), 6.76-6.72 (m, 2 H);  $^{13}C$  NMR: (100 MHz,  $CDCl_3$ )  $\delta$  152.3, 141.7, 134.2, 131.8, 128.9, 128.4, 127.7, 123.5, 117.9, 111.9, 93.6; MS (EI)  $m/z$  (relative intensity) 228.2 (100), 192.1 (31), 62.7 (94)  $[M]^+$ ; HRMS  $m/z$  (ESI) calcd. for  $C_{13}H_{10}N_2Cl$  ( $M + H$ ) $^+$  229.0527, found 229.0532.


### 9. 2-(2,4-Difluorophenyl)pyrazolo[1,5-*a*]pyridine (3i)



**3i**


The reaction of **1a** (39.6 mg, 0.20 mmol), 1-ethynyl-2,4-difluorobenzene (85.4 mg, 0.60 mmol), CuI (3.8 mg, 10 mol %),  $Ag_2CO_3$  (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 35.2 mg (77%) of **3i**: white solid; m.p. 96-98 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{max}$  1919, 1896, 1765, 1624, 1601, 1515, 1477, 1265, 1140, 973, 844, 767  $cm^{-1}$ ;  $^1H$  NMR: (400 MHz,  $CDCl_3$ )  $\delta$  8.46 (d,  $J = 6.4$  Hz, 1 H), 8.14 (dd,  $J = 8.4, 15.2$  Hz, 1 H), 7.52 (d,  $J = 8.8$  Hz, 1 H), 7.09 (t,  $J = 8.0$  Hz, 1 H), 7.01-6.85 (m, 3 H), 6.75 (d,  $J = 6.4$  Hz, 1 H);  $^{13}C$  NMR: (100 MHz,  $CDCl_3$ )  $\delta$  162.9 (dd,  $J = 11.8, 213.4$  Hz), 160.4 (dd,  $J = 12.3, 216.9$  Hz), 147.2, 141.4, 130.0 (dd,  $J = 4.4, 10.0$  Hz), 128.3, 123.4, 118.1, 117.6 (dd,  $J = 3.2, 11.3$  Hz), 112.1, 111.7 (dd,  $J = 3.5, 20.5$  Hz), 104.4 (t,  $J = 26.1$  Hz), 97.0 (d,  $J = 10.8$  Hz); MS (EI)  $m/z$  (relative intensity) 230.2 (100)  $[M]^+$ ; HRMS  $m/z$  (ESI) calcd. for  $C_{13}H_9N_2F_2$  ( $M + H$ ) $^+$  231.0728, found 231.0733.

### 10. 2-(3,5-difluorophenyl)pyrazolo[1,5-*a*]pyridine (3j)



The reaction of **1a** (39.6 mg, 0.20 mmol), 3-ethynylthiophene (74  $\mu$ l, 0.60 mmol), CuI (3.8 mg, 10 mol %), Ag<sub>2</sub>CO<sub>3</sub> (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 29.1 mg (63%) of **3j**: white solid; m.p. 99-102 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\max}$  1919, 1896, 1633, 1602, 1512, 1419, 1115, 989, 763 cm<sup>-1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.44 (d, *J* = 7.2 Hz, 1 H), 7.54-7.45 (m, 3 H), 7.14-7.08 (m, 1 H), 6.83-6.73 (m, 3 H); <sup>13</sup>C NMR: (100 MHz, CDCl<sub>3</sub>)  $\delta$  163.3 (dd, *J* = 12.4, 246.6 Hz), 151.3, 141.7, 136.6 (t, *J* = 9.6 Hz), 128.5, 123.7, 118.1, 112.4, 109.2 (dd, *J* = 7.8, 19.0 Hz), 103.5 (t, *J* = 25.3 Hz), 94.1; MS (EI) *m/z* (relative intensity) 230.2 (100) [M]<sup>+</sup>; HRMS *m/z* (ESI) calcd. for C<sub>13</sub>H<sub>9</sub>N<sub>2</sub>F<sub>2</sub> (M + H)<sup>+</sup> 231.0728, found 231.0733.

### 11. 2-(Thiophen-3-yl)pyrazolo[1,5-*a*]pyridine (**3l**)




The reaction of **1a** (39.6 mg, 0.20 mmol), 3-ethynylthiophene (59  $\mu$ l, 0.60 mmol), CuI (3.8 mg, 10 mol %), Ag<sub>2</sub>CO<sub>3</sub> (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 26.8 mg (67%) of **3l**: white solid; m.p. 115-118 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\max}$  1630, 1513, 1345, 1326, 1252, 858, 775 cm<sup>-1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.44 (d, *J* = 6.8 Hz, 1 H), 7.76 (d, *J* = 0.4 Hz, 1 H), 7.59 (d, *J* = 4.4 Hz, 1 H), 7.48 (d, *J* = 8.8 Hz, 1 H), 7.39 (s, 1 H), 7.11-7.04 (m, 1 H), 6.72 (t, *J* = 6.8 Hz, 1 H), 6.67 (s, 1 H); <sup>13</sup>C NMR: (100 MHz, CDCl<sub>3</sub>)  $\delta$  149.7, 141.4, 135.0, 128.4, 126.3, 126.0, 123.4, 121.9, 117.7, 111.6, 93.9; MS (EI) *m/z* (relative intensity) 200.2 (80), 62.7 (100) [M]<sup>+</sup>; HRMS *m/z* (ESI) calcd. for C<sub>11</sub>H<sub>9</sub>N<sub>2</sub>S (M + H)<sup>+</sup> 201.0481, found 201.0486.

### 12. 2-(4-Chlorophenyl)-5-benzoylpyrazolo[1,5-*a*]pyridine (**3m**)

The reaction of **1b** (57.7 mg, 0.20 mmol), **2b** (82.0 mg, 0.60 mmol), CuI (3.8 mg, 10 mol %), Ag<sub>2</sub>CO<sub>3</sub> (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 28.2 mg (42%) of **3m**: light yellow solid; m.p. 161-164 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\max}$  1787, 1733, 1657, 1525, 1320, 1260, 831, 705 cm<sup>-1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.53 (d, *J* = 7.0 Hz, 1 H), 7.95 (s,






Supporting Information: S. Ding, Y. Yan, N. Jiao

**3m**

1 H), 7.90 (d,  $J = 8.0$  Hz, 2 H), 7.83 (d,  $J = 7.2$  Hz, 2 H), 7.64 (t,  $J = 6.8$  Hz, 1 H), 7.56-7.50 (m, 2 H), 7.43 (d,  $J = 8.0$  Hz, 2 H), 7.28 (d,  $J = 7.2$  Hz, 1 H), 6.96 (s, 1 H);  $^{13}\text{C}$  NMR: (100 MHz,  $\text{CDCl}_3$ )  $\delta$  194.3, 153.6, 140.2, 137.0, 134.7, 133.7, 132.7, 131.1, 129.7, 129.0, 128.9, 128.5, 128.4, 127.7, 121.8, 111.5, 97.1; MS (EI)  $m/z$  (relative intensity) 332.1 (10), 105.1 (62), 77.0 (100)  $[\text{M}]^+$ ; HRMS  $m/z$  (ESI) calcd. for  $\text{C}_{20}\text{H}_{14}\text{N}_2\text{ClO}$  ( $\text{M} + \text{H}$ ) $^+$  333.0789, found 333.0796.


**13. 2-(4-Chlorophenyl)-5-acetylpyrazolo[1,5-a]pyridine (3n)**



The reaction of **1c** (48.1 mg, 0.20 mmol), **2b** (82.0 mg, 0.60 mmol), CuI (3.8 mg, 10 mol %),  $\text{Ag}_2\text{CO}_3$  (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL)

under oxygen for 48 h afforded 17.8 mg (33%) of **3n**: light yellow solid; m.p. 170-174 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\text{max}}$  1909, 1866, 1683, 1498, 1476, 1357, 1096, 833, 774  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR: (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.46 (d,  $J = 7.2$  Hz, 1 H), 8.14 (s, 1 H), 7.90 (d,  $J = 8.0$  Hz, 2 H), 7.43 (d,  $J = 8.0$  Hz, 2 H), 7.32 (d,  $J = 6.0$  Hz, 1 H), 6.99 (s, 1 H), 2.65 (s, 3 H);  $^{13}\text{C}$  NMR: (100 MHz,  $\text{CDCl}_3$ )  $\delta$  195.6, 153.6, 140.4, 134.7, 133.7, 132.2, 129.0, 128.9, 128.5, 127.7, 119.9, 109.7, 97.3, 26.2; MS (EI)  $m/z$  (relative intensity) 270.1 (8), 200.2 (16), 49.9 (100)  $[\text{M}]^+$ ; HRMS  $m/z$  (ESI) calcd. for  $\text{C}_{15}\text{H}_{12}\text{N}_2\text{ClO}$  ( $\text{M} + \text{H}$ ) $^+$  271.0633, found 271.0631.

**14. 2-(4-Chlorophenyl)-7-benzoylpyrazolo[1,5-a]pyridine (3o)**




The reaction of **1d** (60.2 mg, 0.20 mmol), **2b** (82.0 mg, 0.60 mmol), CuI (3.8 mg, 10 mol %),  $\text{Ag}_2\text{CO}_3$  (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under

oxygen for 48 h afforded 26.3 mg (40%) of **3o**: light yellow solid; m.p. 140-143 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\text{max}}$  2225, 1729, 1599, 1524, 1474, 1437, 1334, 1092, 1013, 822, 770  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR: (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.86 (d,  $J = 7.2$  Hz, 2 H), 7.72 (d,  $J = 8.0$  Hz, 2 H), 7.69-7.58 (m, 2 H), 7.46 (t,  $J = 7.2$  Hz, 2 H), 7.31 (d,  $J = 8.0$  Hz, 2 H), 7.18 (t,  $J = 7.6$  Hz, 1 H), 6.95 (d,  $J = 6.4$  Hz, 1 H), 6.85 (s, 1 H);  $^{13}\text{C}$  NMR: (100 MHz,  $\text{CDCl}_3$ )  $\delta$  189.5, 152.6, 142.3, 136.8, 136.2, 134.3, 133.9, 133.7, 131.4, 129.9, 128.9, 128.7, 128.6, 127.8, 122.7, 120.1, 113.8, 94.2; MS (EI)  $m/z$  (relative


intensity) 332.1 (2), 105.1 (29), 77.0 (100) [M]<sup>+</sup>; HRMS *m/z* (ESI) calcd. for C<sub>20</sub>H<sub>14</sub>N<sub>2</sub>ClO (M + H)<sup>+</sup> 333.0789, found 333.0794.

### 15. 4-Chloro-2-(4-chlorophenyl)pyrazolo[1,5-*a*]pyridine (**3p**)

#### 6-Chloro-2-(4-chlorophenyl)pyrazolo[1,5-*a*]pyridine (**3q**)




**3p**



**3q**

The reaction of **1e** (46.6 mg, 0.20 mmol), **2b** (82.0 mg, 0.60 mmol), CuI (3.8 mg, 10 mol %), Ag<sub>2</sub>CO<sub>3</sub> (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 28.4 mg (54%) of **3p** & **3q** (2.4:1). **3p**: light yellow solid; m.p. 157-160 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\max}$  1899, 1771, 1629, 1510, 1463, 1094, 830, 755 cm<sup>-1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.37 (d, *J* = 6.8 Hz, 1 H), 7.90 (d, *J* = 8.0 Hz, 2 H), 7.42 (d, *J* = 8.0 Hz, 2 H), 7.14 (d, *J* = 7.2 Hz, 1 H), 6.90 (s, 1 H), 6.68 (t, *J* = 7.2 Hz, 1 H); <sup>13</sup>C NMR: (100 MHz, CDCl<sub>3</sub>)  $\delta$  152.7, 140.8, 134.6, 131.2, 129.0, 127.8, 123.8, 122.7, 111.3, 94.1; MS (EI) *m/z* (relative intensity) 262.1 (73), 111.0 (70), 75.1 (100) [M]<sup>+</sup>; HRMS *m/z* (ESI) calcd. for C<sub>13</sub>H<sub>9</sub>N<sub>2</sub>Cl<sub>2</sub> (M + H)<sup>+</sup> 263.0137, found 263.0143. **3q**: light yellow; m.p. 125-128 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\max}$  1765, 1463, 1245, 800 cm<sup>-1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.50 (s, 1 H), 7.86 (d, *J* = 8.0 Hz, 2 H), 7.47-7.39 (m, 3 H), 7.08 (d, *J* = 9.2 Hz, 1 H), 6.78 (s, 1 H); <sup>13</sup>C NMR: (100 MHz, CDCl<sub>3</sub>)  $\delta$  153.0, 140.1, 134.5, 131.3, 129.0, 127.7, 126.6, 125.2, 120.0, 118.1, 94.4; MS (EI) *m/z* (relative intensity) 262.1 (75), 110.9 (83), 75.1 (100) [M]<sup>+</sup>; HRMS *m/z* (ESI) calcd. for C<sub>13</sub>H<sub>9</sub>N<sub>2</sub>Cl<sub>2</sub> (M + H)<sup>+</sup> 263.0137, found 263.0142.

### 16. 2-(4-Chlorophenyl)pyrazolo[1,5-*a*]quinoline (**3r**)




**3r**

The reaction of **1f** (49.7 mg, 0.20 mmol), **2b** (82.0 mg, 0.60 mmol), CuI (3.8 mg, 10 mol %), Ag<sub>2</sub>CO<sub>3</sub> (5.5 mg, 10 mol %), DABCO (44.8 mg, 2.0 equiv), in PhCl (2.0 mL) under oxygen for 48 h afforded 45.5 mg (82%) of **3r**: white solid; m.p. 155-158 °C (*n*-hexane/ethyl acetate); IR: (KBr)  $\nu_{\max}$  1913, 1614, 1462, 1422, 1090, 812, 753 cm<sup>-1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.63 (d, *J* = 8.0 Hz, 1 H), 7.96 (d, *J* = 7.6 Hz, 2 H), 7.72 (d, *J* = 7.6 Hz, 1 H), 7.66 (t, *J* = 7.2 Hz, 1 H), 7.44-7.37 (m, 5 H), 6.82 (s, 1 H);

$^{13}\text{C}$  NMR: (100 MHz,  $\text{CDCl}_3$ )  $\delta$  151.7, 139.4, 134.8, 134.0, 133.7, 132.0, 129.4, 128.9, 128.3, 127.6, 124.8, 124.6, 123.3, 116.5, 115.6, 96.6; MS (EI)  $m/z$  (relative intensity) 278.2 (50), 139.9 (90), 74.7 (100)  $[\text{M}]^+$ ; HRMS  $m/z$  (ESI) calcd. for  $\text{C}_{17}\text{H}_{12}\text{N}_2\text{Cl}$  ( $\text{M} + \text{H}$ ) $^+$  279.0684, found 279.0690.

## Kinetic Isotopic Experiment Study



Compound  $[\text{D}_5]\text{-}\mathbf{1a}$  was synthesized according to the reported procedure.<sup>5</sup> Substrates  $\mathbf{1a}$  (39.6 mg, 0.20 mmol),  $[\text{D}_5]\text{-}\mathbf{1a}$  (40.6 mg, 0.20 mmol), CuI (7.6 mg, 10 mol %),  $\text{Ag}_2\text{CO}_3$  (11.0 mg, 10 mol %), DABCO (89.6 mg, 2.0 equiv) were added to a 20 mL Schlenk tube and the tube was purged with  $\text{O}_2$  for three times, followed by addition of  $\mathbf{2a}$  (132  $\mu\text{L}$ , 0.60 mmol) and PhCl (4.0 mL). The formed mixture was stirred at 125  $^\circ\text{C}$  under  $\text{O}_2$  (1 atm.) for 4 h. The solution was then cooled to rt., diluted with ethyl acetate (15 mL), and evaporated under vacuum. The crude product was purified by column chromatography on silica gel (hexane : ethyl acetate = 10:1) to afford 4.6 mg (6%) of the product. Compared with the standard  $^1\text{H}$  NMR spectrum of  $\mathbf{3a}$ , the integration of the peak at 7.97 ppm was 2.84 instead of 2.00, at 7.48-7.43 ppm was 2.94 instead of 2.00, at 7.40-7.34 ppm was 1.47 instead of 1.00, in 6.80 was 1.20 instead of 1.00.


$$k_{\text{H}}/k_{\text{D}} = (2/0.84 + 2/0.94 + 1/0.47)/3 = (2.38 + 2.13 + 2.13)/3 = 2.21$$

Meanwhile, the percentage of the deuterium incorporation at C-3 position could be calculated as follow:


$$[(1 + 1/2.21) - 1.20]/(1 + 1/2.21) = 17\%$$

This result indicated the protonation process in this transformation.

### $^1\text{H}$ NMR spectrum of the product




### Standard $^1\text{H}$ NMR spectrum of **3a**





## References

- 1 A. Balasubramanian, J. M. McIntosh, V. Snieckus, *J. Org. Chem.* 1970, **35**, 433.
- 2 C. Y. Legault, A. B. Charette, *J. Org. Chem.* 2003, **68**, 7119.
- 3 (a) J. J. Mousseau, A. Fortier, A. B. Charette, *Org. Lett.* 2010, **12**, 516; (b) J. J. Mousseau, J. A. Bull, C. L. Ladd, A. Fortier, D. S. Roman, A. B. Charette, *J. Org. Chem.* 2011, **76**, 8243; (c) Y. Miki, O. Tomii, H. Nakao, M. Kubo, H. Hachiken, S. Takemura, M. Ikeda, *J. Heterocyclic Chem.* 1988, **25**, 327; (d) K. Harju, I. Kylaenlahti, T. Paananen, M. Polamo, J. Nielsen, J. Yli-Kauhaluoma, *J. Comb. Chem.* 2006, **8**, 344; (e) T. Tsuchiya, H. Sashida, *J. Chem. Soc., Chem. Commun.* 1980, 1109.
- 4 W. Chai, J. G. Breitenbucher, A. Kwok, X. Li, V. Wong, N. I. Carruthers, T. W. Lovenberg, C. Mazur, S. J. Wilson, F. U. Axe, T. K. Jones, *Bioorg. Med. Chem. Lett.* 2003, **13**, 1767.
- 5 J. J. Mousseau, J. A. Bull, A. B. Charette, *Angew. Chem. Int. Ed.* 2010, **49**, 1115.




3a










**3a**


















3c







**3d**







3d






3e










3e















3g








3g








3h








3h














3j





0.000







3j







3I











**3m**









3m
























3p

